| Performance Foot & Ankle Specialists, Llc | |
|
714 Chase Pkwy Ste 4, Waterbury, CT 06708-3012 | |
| (203) 755-0489 | |
| (203) 755-7523 |
| Full Name | Performance Foot & Ankle Specialists, Llc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist |
| Location | 714 Chase Pkwy Ste 4, Waterbury, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538655782 | NPI | - | NPPES |
| 008004074 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 959 (Connecticut) | Primary |
| Provider Name | Joel S Segalman |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1598758948 PECOS PAC ID: 4587742929 Enrollment ID: I20080424000675 |
News Archive
Meda Pharmaceuticals Inc. (Meda) today announced the commercial availability of EDLUAR(TM) (zolpidem tartrate sublingual tablets) in the United States. EDLUAR is indicated for the short-term treatment of insomnia characterized by difficulties with falling asleep. EDLUAR is the first available under-the-tongue formulation of zolpidem tartrate, which is the most prescribed treatment for insomnia. Zolpidem tartrate is also the active ingredient in Ambien(R) oral tablets.
Some 7,000 U.S. hospital patients die each year and more than 750,000 are injured as a result of medication mistakes. These errors have many causes, and many potential solutions, according to a Rutgers-Camden nursing scholar who has studied the topic extensively.
The current pandemic of COVID-19 seems to be slowing down in various parts of the world, but is far from controlled, as incidence rates rise in new regions. In the absence of an effective vaccine or therapeutic drug, scientists have relied on supportive medical care to treat the sick.
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that it has completed its previously announced acquisition of the Interactive Voice and Web Response Services (IVRS/IWRS) business of Covance Inc. (NYSE: CVD). Phase Forward purchased the Covance business unit for $10 million in cash. As part of the transaction, Phase Forward and Covance have entered into a multi-year marketing agreement to provide Phase Forward's market-leading InForm™ electronic data capture (EDC) solution and Clarix™ Interactive Response Technology (IRT) application as the preferred EDC and IRT solutions to Covance clients.
A trained scent dog accurately identified whether patients' urine samples had thyroid cancer or were benign (noncancerous) 88.2 percent of the time, according to a new study, to- be presented Friday at the Endocrine Society's 97th annual meeting in San Diego.
› Verified 5 days ago
| Provider Name | Stephen Lazaroff |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1588084362 PECOS PAC ID: 2860766797 Enrollment ID: I20170915002632 |
News Archive
Meda Pharmaceuticals Inc. (Meda) today announced the commercial availability of EDLUAR(TM) (zolpidem tartrate sublingual tablets) in the United States. EDLUAR is indicated for the short-term treatment of insomnia characterized by difficulties with falling asleep. EDLUAR is the first available under-the-tongue formulation of zolpidem tartrate, which is the most prescribed treatment for insomnia. Zolpidem tartrate is also the active ingredient in Ambien(R) oral tablets.
Some 7,000 U.S. hospital patients die each year and more than 750,000 are injured as a result of medication mistakes. These errors have many causes, and many potential solutions, according to a Rutgers-Camden nursing scholar who has studied the topic extensively.
The current pandemic of COVID-19 seems to be slowing down in various parts of the world, but is far from controlled, as incidence rates rise in new regions. In the absence of an effective vaccine or therapeutic drug, scientists have relied on supportive medical care to treat the sick.
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that it has completed its previously announced acquisition of the Interactive Voice and Web Response Services (IVRS/IWRS) business of Covance Inc. (NYSE: CVD). Phase Forward purchased the Covance business unit for $10 million in cash. As part of the transaction, Phase Forward and Covance have entered into a multi-year marketing agreement to provide Phase Forward's market-leading InForm™ electronic data capture (EDC) solution and Clarix™ Interactive Response Technology (IRT) application as the preferred EDC and IRT solutions to Covance clients.
A trained scent dog accurately identified whether patients' urine samples had thyroid cancer or were benign (noncancerous) 88.2 percent of the time, according to a new study, to- be presented Friday at the Endocrine Society's 97th annual meeting in San Diego.
› Verified 5 days ago
| Provider Name | Brittany Marie-noelle Ciaramello |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1104288141 PECOS PAC ID: 3577857176 Enrollment ID: I20191003000264 |
News Archive
Meda Pharmaceuticals Inc. (Meda) today announced the commercial availability of EDLUAR(TM) (zolpidem tartrate sublingual tablets) in the United States. EDLUAR is indicated for the short-term treatment of insomnia characterized by difficulties with falling asleep. EDLUAR is the first available under-the-tongue formulation of zolpidem tartrate, which is the most prescribed treatment for insomnia. Zolpidem tartrate is also the active ingredient in Ambien(R) oral tablets.
Some 7,000 U.S. hospital patients die each year and more than 750,000 are injured as a result of medication mistakes. These errors have many causes, and many potential solutions, according to a Rutgers-Camden nursing scholar who has studied the topic extensively.
The current pandemic of COVID-19 seems to be slowing down in various parts of the world, but is far from controlled, as incidence rates rise in new regions. In the absence of an effective vaccine or therapeutic drug, scientists have relied on supportive medical care to treat the sick.
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that it has completed its previously announced acquisition of the Interactive Voice and Web Response Services (IVRS/IWRS) business of Covance Inc. (NYSE: CVD). Phase Forward purchased the Covance business unit for $10 million in cash. As part of the transaction, Phase Forward and Covance have entered into a multi-year marketing agreement to provide Phase Forward's market-leading InForm™ electronic data capture (EDC) solution and Clarix™ Interactive Response Technology (IRT) application as the preferred EDC and IRT solutions to Covance clients.
A trained scent dog accurately identified whether patients' urine samples had thyroid cancer or were benign (noncancerous) 88.2 percent of the time, according to a new study, to- be presented Friday at the Endocrine Society's 97th annual meeting in San Diego.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Performance Foot & Ankle Specialists, Llc 714 Chase Pkwy Ste 4, Waterbury, CT 06708-3012 Ph: (203) 755-0489 | Performance Foot & Ankle Specialists, Llc 714 Chase Pkwy Ste 4, Waterbury, CT 06708-3012 Ph: (203) 755-0489 |
News Archive
Meda Pharmaceuticals Inc. (Meda) today announced the commercial availability of EDLUAR(TM) (zolpidem tartrate sublingual tablets) in the United States. EDLUAR is indicated for the short-term treatment of insomnia characterized by difficulties with falling asleep. EDLUAR is the first available under-the-tongue formulation of zolpidem tartrate, which is the most prescribed treatment for insomnia. Zolpidem tartrate is also the active ingredient in Ambien(R) oral tablets.
Some 7,000 U.S. hospital patients die each year and more than 750,000 are injured as a result of medication mistakes. These errors have many causes, and many potential solutions, according to a Rutgers-Camden nursing scholar who has studied the topic extensively.
The current pandemic of COVID-19 seems to be slowing down in various parts of the world, but is far from controlled, as incidence rates rise in new regions. In the absence of an effective vaccine or therapeutic drug, scientists have relied on supportive medical care to treat the sick.
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that it has completed its previously announced acquisition of the Interactive Voice and Web Response Services (IVRS/IWRS) business of Covance Inc. (NYSE: CVD). Phase Forward purchased the Covance business unit for $10 million in cash. As part of the transaction, Phase Forward and Covance have entered into a multi-year marketing agreement to provide Phase Forward's market-leading InForm™ electronic data capture (EDC) solution and Clarix™ Interactive Response Technology (IRT) application as the preferred EDC and IRT solutions to Covance clients.
A trained scent dog accurately identified whether patients' urine samples had thyroid cancer or were benign (noncancerous) 88.2 percent of the time, according to a new study, to- be presented Friday at the Endocrine Society's 97th annual meeting in San Diego.
› Verified 5 days ago
Bruce & Marilyn Vinokur Foot Care Group Llc Podiatrist Medicare: Medicare Enrolled Practice Location: 1211 W Main St, Waterbury, CT 06708 Phone: 203-755-2050 Fax: 203-755-0131 | |
Charles T Arena, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 1389 West Main Street, Suite 222, Waterbury, CT 06708 Phone: 203-757-9200 | |
Dr. Marilyn M Vinokur, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1211 W Main St, Waterbury, CT 06708 Phone: 203-755-2050 Fax: 203-755-0131 | |
Dr. Peter T Labarbera, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 389 Highland Ave, Waterbury, CT 06708 Phone: 203-754-0879 Fax: 203-757-4123 | |
Dr. Samuel Kellner, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 171 Grandview Ave Ste 104, Waterbury, CT 06708 Phone: 203-753-2048 Fax: 203-753-5891 | |
Michael Z Fein Dpm Pc Podiatrist Medicare: Medicare Enrolled Practice Location: 714 Chase Pkwy, Suite 4, Waterbury, CT 06708 Phone: 203-755-0489 Fax: 203-755-7523 | |
Waterbury Podiatry Consultants Podiatrist Medicare: Medicare Enrolled Practice Location: 171 Grandview Ave, Suite 104, Waterbury, CT 06708 Phone: 203-753-2048 Fax: 203-753-5891 |